Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Pluri"},{"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New data Supporting the sAfety and Efficacy Profile of AJOVY","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Teva Pharmaceutical Industries"}]

Teva Pharmaceutical Industries

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

New data Supporting the sAfety and Efficacy Profile of AJOVY

Details:

Combined review of Phase 3 studies with fremanezumab indicates positive cardiovascular safety profile in adult patients. Additional data on injection-related adverse reactions provide new guidance to healthcare professionals for the optimal selection of injection sites.

Lead Product(s): Fremanezumab

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ajovy

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 21, 2021

ASK
US

Upload
your Pipeline Activity

Pluri

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

Details:

Based on the review, the DMC concluded that the CLI study is unlikely to meet the primary endpoint by the time of the final analysis. Company to terminate the CLI study of PLX-PAD to focus on different therapeutic areas in its pipeline.

Lead Product(s): PLX-PAD

Therapeutic Area: Cardiology/Vascular Diseases Product Name: PLX-PAD

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 09, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY